HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Microbiome Therapy Firm’s COVID-19 Medical Food Research Landed On US FDA’s Drug Study Menu

Executive Summary

Medical food is “for the specific dietary management of a disease or condition for which distinctive nutritional requirements … are established by medical evaluation,” but no distinctive nutritional requirements are established for COVID-19, FDA says. Kaleido says in SEC filing that it “intends to continue with its plans to submit an IND for KB109 in support of future clinical research.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel